SAN DIEGO, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2012. Revenues were $1.6 million for the second quarter of 2012 compared with $0.8 million for the second quarter of 2011, reflecting ongoing reimbursements from Astellas Pharma Inc. for costs and expenses related to the development of TransVax™, Vical’s therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients. The net loss was $7.9 million, or $0.09 per share, for the second quarter of 2012, compared with $8.4 million, or $0.12 per share, for the second quarter of 2011.
